146 related articles for article (PubMed ID: 37545524)
1. Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge model.
Assil S; Buters TP; Hameeteman PW; Hallard C; Treijtel N; Niemeyer-Van der Kolk T; de Kam ML; Florencia EFIII; Prens EP; van Doorn MBA; Rissmann R; Klarenbeek NB; Jansen MAA; Moerland M
Front Immunol; 2023; 14():1197650. PubMed ID: 37545524
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive, Multimodal Characterization of an Imiquimod-Induced Human Skin Inflammation Model for Drug Development.
van der Kolk T; Assil S; Rijneveld R; Klaassen ES; Feiss G; Florencia E; Prens EP; Burggraaf J; Moerland M; Rissmann R; van Doorn MBA
Clin Transl Sci; 2018 Nov; 11(6):607-615. PubMed ID: 29768709
[TBL] [Abstract][Full Text] [Related]
3. Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers.
Buters TP; Hameeteman PW; Jansen IME; van Hindevoort FC; Ten Voorde W; Grievink HW; Schoonakker M; de Kam ML; Gilroy DW; Feiss G; Rissmann R; Jansen MAA; Burggraaf J; Moerland M
Clin Pharmacol Ther; 2022 Apr; 111(4):964-971. PubMed ID: 34935141
[TBL] [Abstract][Full Text] [Related]
4. The oral IRAK4 inhibitors zabedosertib and BAY1830839 suppress local and systemic immune responses in a randomized trial in healthy male volunteers.
Jodl SJ; Ten Voorde W; Klein S; Wagenfeld A; Zollmann FS; Feldmüller M; Klarenbeek NB; de Bruin DT; Jansen MAA; Rissmann R; Rohde B; Moerland M
Clin Transl Sci; 2024 Mar; 17(3):e13771. PubMed ID: 38511583
[TBL] [Abstract][Full Text] [Related]
5. Omiganan Enhances Imiquimod-Induced Inflammatory Responses in Skin of Healthy Volunteers.
Niemeyer-van der Kolk T; Assil S; Buters TP; Rijsbergen M; Klaassen ES; Feiss G; Florencia E; Prens EP; Burggraaf J; van Doorn MBA; Rissmann R; Moerland M
Clin Transl Sci; 2020 May; 13(3):573-579. PubMed ID: 32043302
[TBL] [Abstract][Full Text] [Related]
6. Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation.
Shokrian Zeini M; Haddadi NS; Shayan M; Shokrian Zeini M; Kazemi K; Solaimanian S; Abdollahifar MA; Hedayatyanfard K; Dehpour AR
Int Immunopharmacol; 2021 Nov; 100():108160. PubMed ID: 34583123
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of Imiquimod enhanced ALA-PDT on cutaneous squamous cell carcinoma.
Bhatta AK; Wang P; Keyal U; Zhao Z; Ji J; Zhu L; Wang X; Zhang G
Photodiagnosis Photodyn Ther; 2018 Sep; 23():273-280. PubMed ID: 30030167
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod.
Ueyama A; Yamamoto M; Tsujii K; Furue Y; Imura C; Shichijo M; Yasui K
J Dermatol; 2014 Feb; 41(2):135-43. PubMed ID: 24387343
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod-induced ex vivo model of psoriatic human skin via interleukin-17A signalling of T cells and Langerhans cells.
Carlos ECDS; Cristovão GA; Silva AA; Ribeiro BCS; Romana-Souza B
Exp Dermatol; 2022 Nov; 31(11):1791-1799. PubMed ID: 36054147
[TBL] [Abstract][Full Text] [Related]
10. A requirement for slc15a4 in imiquimod-induced systemic inflammation and psoriasiform inflammation in mice.
Griffith AD; Zaidi AK; Pietro A; Hadiono M; Yang JS; Davis R; Popkin DL
Sci Rep; 2018 Sep; 8(1):14451. PubMed ID: 30262916
[TBL] [Abstract][Full Text] [Related]
11. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.
Huang SW; Chen YJ; Wang ST; Ho LW; Kao JK; Narita M; Takahashi M; Wu CY; Cheng HY; Shieh JJ
J Dermatol Sci; 2016 Oct; 84(1):59-70. PubMed ID: 27449383
[TBL] [Abstract][Full Text] [Related]
12. Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways.
Xu J; Duan X; Hu F; Poorun D; Liu X; Wang X; Zhang S; Gan L; He M; Zhu K; Ming Z; Chen H
J Dermatol Sci; 2018 Feb; 89(2):127-135. PubMed ID: 29137840
[TBL] [Abstract][Full Text] [Related]
13. Procyanidin B2 3,3''-di-O-gallate ameliorates imiquimod-induced skin inflammation by suppressing TLR7 signaling through the inhibition of endosomal acidification in dendritic cells.
Sawa T; Endo K; Nakashima A; Tanaka Y; Makabe H; Tanaka S
Int Immunopharmacol; 2023 Aug; 121():110444. PubMed ID: 37295030
[TBL] [Abstract][Full Text] [Related]
14. Validation of the cantharidin-induced skin blister as an in vivo model of inflammation.
Dinh PH; Corraza F; Mestdagh K; Kassengera Z; Doyen V; Michel O
Br J Clin Pharmacol; 2011 Dec; 72(6):912-20. PubMed ID: 21595743
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of IL-17-committed T cells in a murine psoriasis model by a vitamin D analogue.
Kusuba N; Kitoh A; Dainichi T; Honda T; Otsuka A; Egawa G; Nakajima S; Miyachi Y; Kabashima K
J Allergy Clin Immunol; 2018 Mar; 141(3):972-981.e10. PubMed ID: 28870465
[TBL] [Abstract][Full Text] [Related]
16. The TLR7 agonist imiquimod selectively inhibits IL-4-induced IgE production by suppressing IgG1/IgE class switching and germline ε transcription through the induction of BCL6 expression in B cells.
Yoon HK; Shim YS; Kim PH; Park SR
Cell Immunol; 2019 Apr; 338():1-8. PubMed ID: 30850088
[TBL] [Abstract][Full Text] [Related]
17. A systematic comparison of the effect of topically applied anthraquinone aglycones to relieve psoriasiform lesion: The evaluation of percutaneous absorption and anti-inflammatory potency.
Lin CF; Chuang SY; Huang TH; Nguyen TMH; Wang PW; Alalaiwe A; Fang JY
Biomed Pharmacother; 2022 Jan; 145():112482. PubMed ID: 34915669
[TBL] [Abstract][Full Text] [Related]
18. Different Spatial and Temporal Roles of Monocytes and Monocyte-Derived Cells in the Pathogenesis of an Imiquimod Induced Lupus Model.
Nomura A; Mizuno M; Noto D; Aoyama A; Kuga T; Murayama G; Chiba A; Miyake S
Front Immunol; 2022; 13():764557. PubMed ID: 35371102
[TBL] [Abstract][Full Text] [Related]
19. Calcipotriol and betamethasone dipropionate exhibit different immunomodulatory effects on imiquimod-induced murine psoriasiform dermatitis.
Takeoka S; Shimizu T; Kamata M; Hau CS; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Dermatol; 2020 Feb; 47(2):155-162. PubMed ID: 31762070
[TBL] [Abstract][Full Text] [Related]
20. Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.
Hartmann AK; Bartneck J; Pielenhofer J; Meiser SL; Arnold-Schild D; Klein M; Stassen M; Schild H; Muth S; Probst HC; Langguth P; Grabbe S; Radsak MP
Front Immunol; 2023; 14():1238861. PubMed ID: 37727790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
